My Portfolio
My Watchlists
Profile & Performance
Smart Portfolio
Find & Follow Experts
Top Lists
Top Experts
Make Better, Data Driven Investment Decisions
TipRanks tools are all you need to make data-driven investment decisions, conduct comprehensive stock research, find new investment ideas, analyze your portfolio, and follow the best-performing Wall Street experts.
About Us
Plans & Pricing
Fate Therapeutics (FATE)
NASDAQ:FATE
FATE nasdaq
United States
Fate Therapeutics

Fate Therapeutics Stock Analysis & Ratings

Fate Therapeutics Stock Analysis Overview

Smart Score
7
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Fate Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

FATE

FATE Stock Stats

Previous Close$52.6
Open$53.02
Bid0 x 0
Ask0 x 0
Today’s Range$47.01 - $53.02
52-Week Range$47.01 - $121.16
Volume1.23M
Average Volume1.00M
Market Cap$4.58B
Beta1.46
P/E Ratio-22.6
EPS-2.12
Earnings DateMar 07, 2022

Company Description

Fate Therapeutics

Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Sector
Healthcare
Industry
Biotechnology
CEO
J. Scott Wolchko
Employees
356
ISIN
US31189P1021
Address
3535 General Atomics Court, San Diego, CA, 92121, US

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

FATE FAQ

What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $47.01 and its highest was $121.16 in the past 12 months.
    What is Fate Therapeutics’s market cap?
    Fate Therapeutics’s market cap is $4.58B.
      What is Fate Therapeutics’s price target?
      The average price target for Fate Therapeutics is $100.00. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $145.00 ,the lowest forecast is $60.00. The average price target represents 108.33% Increase from the current price of $48.
        What do analysts say about Fate Therapeutics?
        Fate Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
          When is Fate Therapeutics’s upcoming earnings report date?
          Fate Therapeutics’s upcoming earnings report date is Mar 07, 2022 which is in 92 days.
            How were Fate Therapeutics’s earnings last quarter?
            Fate Therapeutics released its earnings results on Nov 04, 2021. The company reported -$0.45 earnings per share for the quarter, beating the consensus estimate of -$0.569 by $0.119.
              Is Fate Therapeutics overvalued?
              According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
                Does Fate Therapeutics pay dividends?
                Fate Therapeutics does not currently pay dividends.
                What is Fate Therapeutics’s EPS estimate?
                Fate Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Fate Therapeutics have?
                Fate Therapeutics has 95,490,000 shares outstanding.
                  What happened to Fate Therapeutics’s price movement after its last earnings report?
                  Fate Therapeutics reported an EPS of -$0.45 in its last earnings report, beating expectations of -$0.569. Following the earnings report the stock price went up 1.722%.
                    Which hedge fund is a major shareholder of Fate Therapeutics?
                    Among the largest hedge funds holding Fate Therapeutics’s share is ARK Investment Management LLC. It holds Fate Therapeutics’s shares valued at 646M.

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis